Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Signaturefd LLC

Signaturefd LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,375 shares of the biopharmaceutical company’s stock after selling 7,231 shares during the quarter. Signaturefd LLC’s holdings in Bristol-Myers Squibb were worth $3,795,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at $27,000. ESL Trust Services LLC purchased a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $34,000. MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at $39,000. Finally, Fairman Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.5 %

NYSE BMY traded up $0.23 during mid-day trading on Friday, reaching $49.95. 9,434,419 shares of the stock were exchanged, compared to its average volume of 15,441,344. The business’s fifty day simple moving average is $45.01 and its 200 day simple moving average is $46.59. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock has a market capitalization of $101.25 billion, a PE ratio of -16.11, a PEG ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.03.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter in the previous year, the business earned $1.75 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BMY. Barclays increased their price target on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Jefferies Financial Group upped their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen boosted their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research report on Monday, August 12th. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $54.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.